Related Experiment Video
Updated: Aug 22, 2025
10:46
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
10.7K
What Do We Know So Far about Ofatumumab for Relapsing Multiple Sclerosis? A Meta-Analytical Study
Hafiza Munazza Taj1, Maryam Talib2, Sania Siddiqa3
1Research and Publications, Fatima Jinnah Medical University, Lahore 54000, Pakistan.
Healthcare (Basel, Switzerland)
|November 11, 2022
Summary
Ofatumumab effectively reduces B cells in relapsing multiple sclerosis. This analysis of four trials shows it significantly decreases MRI lesions and relapse rates, offering a promising treatment option.
Area of Science:
- Neuroimmunology
- Clinical Neurology
- Pharmacology
Background:
- Relapsing multiple sclerosis (MS) is a chronic autoimmune disease impacting the central nervous system.
- B cell depletion is a therapeutic strategy for managing MS progression.
- Ofatumumab is an FDA-approved monoclonal antibody targeting B cells.
Purpose of the Study:
- To evaluate the efficacy of ofatumumab in reducing disease activity in relapsing MS.
- To analyze outcomes from randomized controlled trials (RCTs) concerning MRI lesions and relapse rates.
Main Methods:
- Meta-analysis of four randomized controlled trials.
- Assessment of Gadolinium-enhancing T1 lesions on MRI scans.
- Evaluation of relapse rates.
Main Results:
- Ofatumumab significantly reduced Gadolinium-enhancing T1 lesions (Cohen’s d = -0.44, p < 0.00001).
- A 46% reduction in relapse rate was observed post-ofatumumab administration (RR = 0.54, p < 0.00001).
Conclusions:
- Ofatumumab demonstrates significant efficacy in reducing key markers of disease activity in relapsing MS.
- Further research from ongoing trials is warranted to solidify these findings.
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
157
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
157
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
214
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
214